Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK

Key Points

• Vanguard Group increased its stake in Stoke Therapeutics by 7.4% in Q3, owning 3,163,874 shares (about 5.54% of the company) worth roughly $74.35 million.
• Insiders sold stock on December 8th—General Counsel Jonathan Allan sold 3,978 shares and Director Edward M. Kaye sold 13,430 shares—reducing their holdings; insiders now own about 9.5% of the company.
• Analysts have lifted price targets and ratings recently (HC Wainwright and UBS at $50, Guggenheim at $60, Wolfe at $40), leaving an average target of about $39.25 and a consensus rating of "Moderate Buy."

Vanguard Group Inc. raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,163,874 shares of the company's stock after acquiring an additional 217,616 shares during the period. Vanguard Group Inc. owned about 5.54% of Stoke Therapeutics worth $74,351,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after acquiring an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Stoke Therapeutics by 263.3% during the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company's stock valued at $85,000 after purchasing an additional 5,427 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock worth $108,000 after purchasing an additional 2,384 shares during the last quarter. Finally, Strs Ohio purchased a new position in Stoke Therapeutics during the third quarter worth about $150,000.

Stoke Therapeutics Stock Performance

STOK opened at $35.48 on Friday. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $39.81. The firm has a 50-day moving average of $32.19 and a 200 day moving average of $28.94. The firm has a market cap of $2.03 billion, a P/E ratio of 52.96 and a beta of 1.07.

Insider Transactions at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the completion of the transaction, the general counsel directly owned 11,831 shares of the company's stock, valued at $381,904.68. This represents a 25.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 13,430 shares of the firm's stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the sale, the director owned 49,124 shares of the company's stock, valued at approximately $1,585,231.48. The trade was a 21.47% decrease in their position. The disclosure for this sale is available in the SEC filing. 9.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on STOK shares. HC Wainwright increased their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, December 15th. UBS Group set a $50.00 target price on Stoke Therapeutics in a research note on Monday, December 15th. Guggenheim initiated coverage on Stoke Therapeutics in a report on Thursday, February 5th. They issued a "buy" rating and a $60.00 target price for the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Finally, Wolfe Research began coverage on Stoke Therapeutics in a report on Monday, February 23rd. They set an "outperform" rating and a $40.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $39.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.